menu
    • menu

    Company profile for Novaliq

    NEW Drugs in Dev: 4
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. EyeSol® is designed to unfold the full potential of eye care treatments. EyeSol® enhances corneal residence time and ocular coverage, providing better bioavailability and faster onset. EyeSol® pr...
    Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. EyeSol® is designed to unfold the full potential of eye care treatments. EyeSol® enhances corneal residence time and ocular coverage, providing better bioavailability and faster onset. EyeSol® products are water-free and therefore obviate preservatives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NovaliqGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Im Neuenheimer Feld 515 69120 Heidelberg
    Telephone
    Telephone
    +49 6221 50259-0
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novaliq.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/novaliq/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/novaliq

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novaliq Advances NOV05 In FDA-Cleared Phase II Trial
    Novaliq Advances NOV05 In FDA-Cleared Phase II Trial

    26 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260126710784/en/Novaliq-Receives-FDA-IND-Clearance-to-Advance-NOV05-in-a-Phase-II-Clinical-Trial-in-Non-infectious-Anterior-Uveitis

    BUSINESSWIRE
    26 Jan 2026
    Share Share
    Hengrui’s Heng Qin Gets Nod For Dry Eye Linked To MGD
    Hengrui’s Heng Qin Gets Nod For Dry Eye Linked To MGD

    08 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250708514269/en/Breakthrough-in-Ophthalmology-Hengruis-Heng-Qin-Perfluorohexyloctane-Eye-Drops-Approved-as-First-Treatment-for-Dry-Eye-Disease-Associated-with-MGD

    BUSINESSWIRE
    08 Jul 2025
    Share Share
    Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
    Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

    29 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240729979383/en

    BUSINESSWIRE
    29 Jul 2024
    Share Share
    EMA Accepts Novaliq’s MAA for CyclASol for the Treatment of Dry Eye Disease
    EMA Accepts Novaliq’s MAA for CyclASol for the Treatment of Dry Eye Disease

    24 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230824122107/en

    BUSINESSWIRE
    24 Aug 2023
    Share Share
    Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE from Novaliq
    Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE from Novaliq

    18 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230718821365/en

    BUSINESSWIRE
    18 Jul 2023
    Share Share
    Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03
    Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03

    13 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230612304814/en

    BUSINESSWIRE
    13 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search